Guardian Wealth Management Inc. Takes Position in Zoetis Inc. $ZTS

Guardian Wealth Management Inc. bought a new stake in Zoetis Inc. (NYSE:ZTS) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 64,124 shares of the company’s stock, valued at approximately $4,608,000. Zoetis makes up approximately 2.3% of Guardian Wealth Management Inc.’s investment portfolio, making the stock its 20th biggest position.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. RFG Advisory LLC lifted its stake in Zoetis by 4.9% during the fourth quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock worth $215,000 after purchasing an additional 80 shares during the period. Financial Engines Advisors L.L.C. raised its holdings in shares of Zoetis by 4.4% in the 3rd quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock worth $299,000 after buying an additional 87 shares in the last quarter. Physician Wealth Advisors Inc. lifted its position in shares of Zoetis by 17.4% during the 1st quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock worth $73,000 after buying an additional 91 shares during the period. Smithfield Trust Co lifted its position in shares of Zoetis by 4.2% during the 4th quarter. Smithfield Trust Co now owns 2,294 shares of the company’s stock worth $290,000 after buying an additional 92 shares during the period. Finally, Howland Capital Management LLC boosted its stake in Zoetis by 4.5% in the 2nd quarter. Howland Capital Management LLC now owns 2,137 shares of the company’s stock valued at $333,000 after buying an additional 92 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Trading Down 0.8%

ZTS stock opened at $75.70 on Friday. The business has a fifty day moving average price of $75.53 and a 200 day moving average price of $93.85. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. Zoetis Inc. has a fifty-two week low of $71.00 and a fifty-two week high of $155.15. The stock has a market capitalization of $31.28 billion, a price-to-earnings ratio of 12.47, a P/E/G ratio of 1.77 and a beta of 0.73.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter in the prior year, the business earned $1.76 earnings per share. The business’s revenue for the quarter was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Analysts expect that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. BNP Paribas Exane lowered their price target on Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 11th. Morgan Stanley set a $85.00 price objective on Zoetis in a report on Friday, August 7th. UBS Group lowered their target price on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a report on Friday, August 7th. TD Cowen dropped their target price on shares of Zoetis from $104.00 to $94.00 and set a “buy” rating for the company in a research report on Tuesday, August 25th. Finally, Zacks Research cut shares of Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. Eight investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $107.43.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.